Damora Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses | ||||
| Research and development | $25,475 | $1,416 | $74,792 | $3,559 |
| General and administrative | 11,388 | 1,740 | 27,876 | 5,617 |
| Total operating expenses | 36,863 | 3,156 | 102,668 | 9,176 |
| Loss from operations | (36,863) | (3,156) | (102,668) | (9,176) |
| Other income (expense), net | ||||
| Gain on sale of IP | 750 | — | 750 | — |
| Interest income, net | 4,159 | 42 | 11,288 | 166 |
| Foreign exchange transaction loss, net | (37) | (19) | (21) | (87) |
| Total other income, net | 4,872 | 23 | 12,017 | 79 |
| Loss before income tax expense | (31,991) | (3,133) | (90,651) | (9,097) |
| Income tax expense | — | — | (297) | (6) |
| Net loss | $(31,991) | $(3,133) | $(90,948) | $(9,103) |
| Net loss per share, basic and diluted, Series B Preferred Shares | $(400.40) | $— | $(1,188.20) | $— |
| Weighted-average Series B non-voting convertible preferred shares outstanding, basic and diluted | 16,366 | — | 16,366 | — |
| Net loss per share, basic and diluted, Series C Preferred Shares | $(400.40) | $— | $(1,188.20) | $— |
| Weighted-average Series C non-voting convertible preferred shares outstanding, basic and diluted | 1,722 | — | 7,888 | — |
| Net loss per share, basic and diluted, ordinary shares | $(0.40) | $(2.36) | $(1.19) | $(6.88) |
| Weighted-average number of shares used in computing net loss per ordinary share, basic and diluted | 61,810,033 | 1,327,039 | 52,289,247 | 1,323,886 |
| Other comprehensive (loss) income, net of tax | ||||
| Currency translation gain (loss) | $9 | $14 | $(61) | $726 |
| Unrealized loss on marketable securities, net of tax | (974) | - | (974) | - |
| Other comprehensive (loss) income, net of tax | (965) | 14 | (1,035) | 726 |
| Total comprehensive loss | $(32,956) | $(3,119) | $(91,983) | $(8,377) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.